Alnylam Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|
| Revenue | $89.9M | $47.2M | $100.0M | $100.5M | $96.2M |
| ONPATTRO | — | — | — | — | — |
| AMVUTTRA | — | — | — | — | — |
| GIVLAARI | — | — | — | — | — |
| OXLUMO | — | — | — | — | — |
| Collaboration and other revenue | — | — | — | — | — |
| Royalty revenue | — | — | — | — | — |
| Cost of Revenue | $0 | — | — | — | — |
| Gross Profit | $89.9M | — | — | — | — |
| Gross Margin | 100.0% | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $390.6M | $382.4M | $106.4M | $108.7M | $96.9M |
| SG&A Expense | $199.4M | $89.4M | $37.7M | $39.9M | $27.1M |
| Operating Income | $-500.1M | $-424.6M | $-44.1M | $-48.1M | $-27.8M |
| Operating Margin | -556.2% | -900.3% | -44.1% | -47.9% | -28.9% |
| Interest Expense | — | — | — | — | $872.0K |
| Pretax Income | $-490.9M | $-410.1M | $-43.0M | $-47.0M | $-25.5M |
| Income Tax Expense | $0 | $0 | $514.0K | $582.0K | $719.0K |
| Net Income | $-490.9M | $-410.1M | $-43.5M | $-47.6M | $-26.2M |
| Net Margin | -545.9% | -869.6% | -43.5% | -47.3% | -27.3% |
| EPS (Basic) | $-5.42 | $-4.79 | $-1.04 | $-1.14 | — |
| EPS (Diluted) | $-5.42 | $-4.79 | $-1.04 | $-1.14 | — |
| Shares Outstanding (Basic) | 99.7M | 85.9M | 42.3M | 41.8M | — |
| Shares Outstanding (Diluted) | 99.7M | 85.9M | 42.3M | 41.8M | — |
| Dividends Per Share | — | — | — | — | — |